Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21(ras) activated, AP-1-dependent pathway

Kidney International

Volumn 52, Issue 4, 1997, Pages 1016-1027

  Vrtovsnik, François ^a   Couette, Sylviane ^b   Prié, Dominique ^b   Lallemand, Dominique ^b   Friedlander, Gérard ^b  

^a INSERM   (France)

^b NONE

Author keywords

Epithelial cells; HMG CoA reductase inhibitors; Lovastatin; p21(ras)AP 1 mitogenic cascade; Tubular celI proliferation

Indexed keywords

GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PROTEIN P21;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DNA BINDING; DRUG EFFECT; ELECTROPHORETIC MOBILITY; ENZYME INHIBITION; IMMUNOCYTOCHEMISTRY; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MITOGENESIS; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

EID: 0030820468     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.423     Document Type: Article

References (68)

1. WITZGALL R, BROWN D, SCHWARZ C, BONVENTRE JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogeneous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 93:2175-2188, 1994
2. BOHLE A, MACKENSEN-HAEN S, GISE H: Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: A morphometric contribution. Am J Nephrol 7:421-433, 1987
3. HOWIE AJ, ROWLANDS DC, REYNOLDS GM, BARNES AD: Measurement of proliferation in renal biopsy specimens: Evidence of subclinical tubular damage in the nephrotic syndrome. Nephrol Dial Transplant 10:2212-2218, 1995
4. EDDY AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994
5. LANOIX J, D'AGATI V, SZABOLCS M, TRUDEL M: Dysregulation of cellular proliferation and apoptosis mediates human autosomal polcystic kidney disease (ADPKD). Oncogene 13:1153-1160, 1996
6. KLIEM V, JOHNSON RJ, ALPERS CE, YOSHIMURA A, COUSER WG, KOCH KM, FLOEGE J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 49: 666-678, 1996
7. MISKELL CA, SIMPSON DP: Hyperplasia precedes increased glomerular filtration rate in rat remnant kidney. Kidney Int 37:758-766, 1990
8. TERZI F, TICOZZI C, BURTIN M, MOTEL V, BEAUFILS H, LAOUARI D, ASSAEL BM, KLEINKNECHT C: Subtotal but not unilateral nephrectomy induces hyperplasia and protooncogene expression. Am J Physiol 268:F793-F801, 1995
9. FINE LG, HAMMERMAN MR, ABBOUD HE: Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol 2:1163-1170, 1992
10. DU J, WILSON PD: Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 269:C487-C495, 1995
11. WILSON PD, HRENIUK D, GABOW P: Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia. J Cell Physiol 150:360-369, 1992
12. KARIN M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486, 1995
13. COWLEY BD, SMARDO FL, GRANTHAM JJ, CALVET JP: Elevated c-myc protooncogene expression in autosomal recessive polycistic kidney disease. Proc Natl Acad Sci USA 84:8394-8398, 1987
14. KUJUBU DA, NORMAN JT, HERSCHMAN HR, FINE LG: Primary response gene expression in renal hypertrophy and hyperplasia: Evidence for different growth initiation processes. Am J Physiol 260:F823-F827, 1991
15. SCHAFFNER DL, BARRIOS R, MAASEY C, BANEZ EI, OU C-N, RAJAGOPALAN S, AGUILAR-CORDOVA E, LEBOVITZ RM, OVERBEEK PA, LIEBERMAN MW: Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 142:1051-1060, 1993
16. TRUDEL M, D'AGATI V, COSTANTINI F: C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39:665-671, 1991
17. CASEY PJ: Protein lipidation in cell signaling. Science 268:221-225, 1995
18. GIBBS JB, OLIFF A, KOHL NE: Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994
19. GOLDSTEIN JL, BROWN MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
20. MILLER AC, SAMID D: Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21-ras isoprenylation. Int J Cancer 60:249-254, 1995
21. SEBTI SM, TKALCEVIC GT, JANI JP: Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Comm 3:141-147, 1991
22. VOGT A, QIAN Y, MCGUIRE TF, HAMILTON AD, SEBTI SM: Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991-1999, 1996
23. LARSSON O: Effect of virus-transformation and growth factor stimulation on isoprene biosynthesis in human fibroblasts: A correlation to cell growth. Cancer Biochem Biophys 14:243-256, 1995
24. DAVIS MA, CHANG SH, TRUMP BF: Differential sensitivity of normal and H-ras oncogene-transformed rat kidney epithelial cells to okadaic acid-induced apoptosis. Toxicol Appl Pharmacol 141:93-101, 1996
25. COLOTTA F, POLENTARUTTI N, SIRONI M, MANTOVANI A: Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 267:18278-18283, 1992
26. KITA T, BROWN MS, GOLDSTEIN JL: Feedback regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 66:1094-1100, 1980
27. VINAY P, GOUGOUX A, LEMIEUX G: Isolation of a pure suspension of rat proximal tubules. Am J Physiol 241:F403-F411, 1981
28. FRIEDLANDER G, AMIEL C: Protein kinase C activation has dissimilar effects on sodium-coupled uptakes in renal proximal tubular cells in primary culture. J Biol Chem 264:3935-3941, 1989
29. MENAA C, VRTOVSNIK F, FRIEDLANDER G, CORVOL M, GARABÉDIAN M: Insulin-like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production. Studies in cultured mouse kidney cells. J Biol Chem 270:25461-25467, 1995
30. CARMICHAEL J, DEGRAFF WG, GAZDAR AF, MINNA JD, MITCHELL JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:936-942, 1987
31. BRADFORD MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
32. LAEMMLI UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
33. PFARR CM, MECHTA F, SPYROU G, LALLEMAND D, CARILLO S, YANIV M: Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 76:747-760, 1994
34. ABMAYR SM, WORKMAN JL: Nuclear and cytoplasmic extracts from mammalian cells. Cuir Protocols Biol 12:1.1-12.1.9, 1993
35. SNEDECOR GW, COCHRAN WG: Statistical Methods (6th ed). 1972, 593 PP
36. IGAWA T, KANDA S, KANETAKE H, SAITOH Y, ICHIHARA A, TOMITA Y, NAKAMURA T: Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 174:831-838, 1991
37. GIBBS JB, POMPLIANO DL, MOSSER SD, RANDS E, LINGHAM RB, SINGH SB, SCOLNICK EM, KOHL NE, OLIFF A: Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620, 1993
38. LEWIS MP, FINE LG, NORMAN JT: Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Kidney Int 49:48-58, 1996
39. CASEY PJ: Biochemistry of protein prenylation. J Lipid Res 33:1731-1740, 1992
40. DANESI R, MCLELLAN CA, MYERS CE: Specific labelling of isoprenylated proteins: Application to study inhibitors of the post-translational farnesylation and geranylgeranylation. Biochem Biophys Acta 206:637-643, 1995
41. GARCIA AM, ROWELE C, ACKERMANN K, KOWALCZYK JJ, LEWIS MD: Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 268:18415-18418, 1993
42. LERNER EC, QIAN Y, HAMILTON AD, SEBTI SM: Disruption of oncogenic K-ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-26773, 1995
43. DEFEO-JONES D, MCAVOY EM, JONES RE, VUOCOLO GA, HASKELL KM, WEGRZYN RJ, OLIFF A: Lovastatin selectively inhibits ras activation of the 12-O-tetradecanoylphorbol-13-acetate response element in mammalian cells. Mol Cell Biol 11:2307-2310, 1991
44. QIU R-G, CHEN J, MCCORMICK F, SYMONS M: A role for Rho in ras transformation. Proc Natl Acad Sci USA 92:11781-11785, 1995
45. LEBOWITZ PF, DAVIDE JP, PRENDERGAST GC: Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613-6622, 1995
46. KAUFFMANN RC, QIAN Y, VOGT A, SEBTI SM, HAMILTON AD, CARTHEW RW: Activated Drosophila ras1 is selectively suppressed by isoprenyltransferase inhibitors. Proc Natl Acad Sci USA 92:10919-10923, 1995
47. Xu X-Q, MCGUIRE TF, BLASKOVICH MA, SEBTI SM, ROMERO G: Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts. Arch Biochem Biophys 326:233-237, 1996
48. LARSSON SH, HULTGARDH-NILSSON A, KÖLARE S, LUTHMAN J, SEJERSEN T, APERIA A: Serum factors induce C-fos expression and rapid cell proliferation in adolescent but not in infant rat proximal tubule cells. Ped Res 29:263-267, 1991
49. BINÉTRUY B, SMEAL T, KARIN M: Ha-ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature 351:122-127, 1991
50. UBERALL F, KAMPFER S, DOPPLER W, GRUNICKE HH: Activation of c-fos expression by transforming Ha-ras in HC11 mouse mammary epithelial cells is PKC-dependent and mediated by the serum response element. Cell Signal 6:285-297, 1994
51. VINCENT TS, WÜLFERT E, MERLER E: Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Comm 180: 1284-1289, 1991
52. TANNO K, AOKI Y: Phosphorylation of c-jun stimulated in primary cultured rat liver parenchymal cells by a coplanar polychlorinated biphenyl. Biochem J 313:863-866, 1996
53. DECLUE JE, VASS WC, PAPAGEORGE AG, LOWY DR, WILLUMSEN BM: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712-717, 1991
54. WAGNER RW: Antisense research. Nature 1994
55. RODRIGUEZ-VICIANA P, WARNE PH, DHAND R, VANHAESEBROECK B, GOUT I, FRY MJ, WATERFIELD MD, DOWNWARD J: Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 370:527-532, 1994
56. MCDONNELL MP, KASISKE BL, KIM Y, ATLURU D, KEANE WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87, 1993
57. GRANDALIANO G, BISWAS P, CHOUDHURY GG, ABBOUD HE: Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44:503-508, 1993
58. NABESHIMA K, YOSHIMURA A, INUI K, UDA S, SUGENOYA Y, IDEURA T: HMG CoA reductase inhibitor suppresses initial macrophage infiltration and PDGF-induced mesangial cell proliferation in rats with mesangial proliferative nephritis in vivo, (abstract) J Am Soc Nephrol 5:789, 1994
59. CORSINI A, MAGGI FM, CATAPANO AL: Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31:9-27, 1995
60. FALKE P, MATTIASSON I, STAVENOW L, HOOD B: Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl Coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 64:173-176, 1989
61. PAN HY, DEVAULT AR, WANG-IVERSON D, IVASHKIV E, SWANSON BN, SUGERMAN AA: Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128-1135, 1990
62. CORSINI A, PAZZUCCONI F, PFISTER P, PAOLETTI R, SIRTORI CR: Inhibition of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 348:1584, 1996
63. KASISKE BL, O'DONNELL MP, GARVIS WJ, KEANE WF: Pharmacologie treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62:367-374, 1988
64. MCDONNELL MP, KASISKE BL, KATZ SA, SCHMITZ PG, KEANE WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20:651-658, 1992
65. KASISKE BL, O'DONNELL MP, CLEARY MP, KEANE WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
66. GILE RD, COWLEY BD, GATTONE VH, O'DONNELL MP, SWAN SK, GRANTHAM JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26:501-507, 1995
67. SOMA MR, DONETTI E, PAROLINI C, MAZZINI G, FERRARI C, FUMAGALLI R, PAOLETTI R: HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arteriosclerosis Thromb 13: 571-578, 1993
68. JANI PJ, SPECHT S, STEMMLER N, BLANOCK K, SINGH SV, GUPTA V, KATOH A METASTASIS OF B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invas Metastasis 13:314-324, 1993